International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
暂无分享,去创建一个
K. Mansfield | S. Buchbinder | M. Robb | N. Michael | L. Bekker | O. Anzala | F. Sinangil | G. Weverling | G. Gray | J. Goudsmit | D. Barouch | M. Seaman | S. Kik | J. Gilmour | P. Abbink | M. Pau | H. Kibuuka | R. Dolin | G. de Bruyn | L. Baden | J. Hural | Sharon L. King | A. Carville | P. Amornkul | D. Ng'ang'a | R. Dilan | A. Dilraj | S. Roux | Sarah L Clark | L. Maxfield | Kara Brandariz
[1] P. Kaleebu,et al. Adenovirus-Based Vaccines: Comparison of Vectors from Three Species of Adenoviridae , 2010, Journal of Virology.
[2] J. Baeten,et al. Frequent Detection of Human Adenovirus from the Lower Gastrointestinal Tract in Men Who Have Sex with Men , 2010, PloS one.
[3] N. Wolfe,et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. , 2010, Vaccine.
[4] Devan V Mehrotra,et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial , 2008, The Lancet.
[5] Donald K Carter,et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis , 2008, The Lancet.
[6] D. Montefiori,et al. Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.
[7] J. Kublin,et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] K. Mansfield,et al. Magnitude and Phenotype of Cellular Immune Responses Elicited by Recombinant Adenovirus Vectors and Heterologous Prime-Boost Regimens in Rhesus Monkeys , 2008, Journal of Virology.
[9] C. Napoli,et al. Adenovirus Serotype 5 Hexon Mediates Liver Gene Transfer , 2008, Cell.
[10] R. Koup,et al. Myeloid and Plasmacytoid Dendritic Cells Are Susceptible to Recombinant Adenovirus Vectors and Stimulate Polyfunctional Memory T Cell Responses , 2007, The Journal of Immunology.
[11] K. Mansfield,et al. Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D , 2007, Journal of Virology.
[12] J. Mascola,et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.
[13] Punnee Pitisuttithum,et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.
[14] P. Jeena,et al. Age Dependence of Adenovirus-Specific Neutralizing Antibody Titers in Individuals from Sub-Saharan Africa , 2006, Journal of Clinical Microbiology.
[15] K. Mansfield,et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity , 2006, Nature.
[16] Kenneth H Mayer,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.
[17] B. Berkhout,et al. Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.
[18] S. Kostense,et al. Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.
[19] Jaap Goudsmit,et al. Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors , 2003, Journal of Clinical Microbiology.
[20] S. Kostense,et al. Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.
[21] R. K. Evans,et al. Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.
[22] Z. Xiang,et al. A Simian Replication-Defective Adenoviral Recombinant Vaccine to HIV-1 Gag 1 , 2003, The Journal of Immunology.
[23] R. M. Burnett,et al. Replication-Defective Vector Based on a Chimpanzee Adenovirus , 2001, Journal of Virology.